Amplia Therapeutics Ltd. is raising AU$27.5 million (US$18.12 million) to advance lead compound narmafotinib (AMP-945), a focal adhesion kinase (FAK) inhibitor, into new indications beyond pancreatic ...

The tissue damage, anatomical distortion, and lack of surgical landmarks caused by the primary treatment present major challenges to surgeons performing salvage RARP.

Current approaches in bioengineering are synthesized and methods for their implementation are suggested for the induction and modulation of trained immunity in the treatment of human diseases.

If the recent heatwaves have highlighted problems with your garden decking or you have recently laid a new deck, Brewers Decorator Centres has ...

These Victorian hallway ideas are full of clever ways to honour your home’s heritage while keeping things beautifully up to ...